ABSTRACT
Introduction: On 18 September 2012, United States health officials began to react to a large outbreak of fungal meningitis traceable to methylprednisolone from a compounding pharmacy in Framingham, Massachusetts. Although the index case was attributed to the opportunistic mold Aspergillus fumigatus, all subsequent cases were due to the dematiaceous mold Exserohilum rostratum, which had previously been an uncommon cause of disease in humans.
Areas covered: In this paper, the authors examine recent advances in the diagnosis and treatment of Exserohilum infection and provide updates on how the innate and acquire immune responses enable clearance of human fungal pathogens.
Expert commentary: The fungal meningitis outbreak of 2012 stretched across 20 states and resulted in 753 cases of central nervous system infection and 64 deaths. In this paper, the authors examine how the outbreak prompted investigators to develop novel diagnostic and therapeutic options that have advanced the study of human fungal pathogens and will benefit patients who are susceptible to invasive mycoses.
Declaration of Interest
MW McCarthy has served as a paid consultant to Allergan. TJ Walsh receives research grants for experimental and clinical antimicrobial pharmacotherapeutics from Astellas, Cubist, Theravance, the Medicines Company, Allergan, Novartis, Merck, and Pfizer. He has served as a consultant to Astellas, Actavis, ContraFect, Drais, iCo, Novartis, Pfizer, Methylgene, SigmaTau, and Trius. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.